Mutant p53 protein as a predictor of survival in endometrial carcinoma

被引:28
|
作者
Strang, P
Nordstrom, B
Nilsson, S
Bergstrom, R
Tribukait, B
机构
[1] UNIV UPPSALA HOSP,DEPT ONCOL,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA,DEPT STAT,S-75120 UPPSALA,SWEDEN
[3] KAROLINSKA INST,DEPT MED RADIAT BIOL,S-10401 STOCKHOLM,SWEDEN
关键词
endometrial carcinoma; prognosis; p53; DNA ploidy; proliferation; nuclear grade;
D O I
10.1016/0959-8049(95)00636-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of mutated p53 protein was studied in paraffin-embedded, formalin-fixed tumour specimens from 183 women with endometrial carcinoma. Fifty-five per cent of the specimens were negative, whereas the staining intensity was weak, moderate or strong in 15, 2 and 28% of cases, respectively. Strong p53 expression (> 75% of the cells stained) was more common in uterine papillary serous cancers and clear cell cancers than in other tumour subtypes (P < 0.001), as well as in poorly differentiated tumours (P < 0.01) and in tumours with nuclear grade 3 (P < 0.0001). Strong p53 expression was also more frequently found in aneuploid tumours (P < 0.0001) and in tumours with a high S-phase fraction (P < 0.001). Strong p53 expression was highly predictive of poor survival in the univariate analysis (P = 0.006) and in the Cox multivariate analysis which included age, stage and grade. However, it lost most of its impact when the strongly prognostic nuclear grade and ploidy were added to the multivariate models. (C) 1996 Published by Elsevier Science Ltd
引用
收藏
页码:598 / 602
页数:5
相关论文
共 50 条
  • [41] MUTANT P53 PROTEIN IMMUNOHISTOCHEMISTRY IN KERATOACANTHOMA AND SQUAMOUS-CELL CARCINOMA OF THE SKIN
    STEPHENSON, TJ
    ROYDS, J
    SILCOCKS, PB
    BLEEHEN, SS
    JOURNAL OF PATHOLOGY, 1992, 168 : A114 - A114
  • [42] Abnormal accumulation of p53 predicts radioresistance leading to poor survival in patients with endometrial carcinoma
    Akiyama, Azusa
    Minaguchi, Takeo
    Fujieda, Kaoru
    Hosokawa, Yoshihiko
    Nishida, Keiko
    Shikama, Ayumi
    Tasaka, Nobutaka
    Sakurai, Manabu
    Ochi, Hiroyuki
    Satoh, Toyomi
    ONCOLOGY LETTERS, 2019, 18 (06) : 5952 - 5958
  • [43] Expression of MDR1 and mutant p53 protein in hepatocellular carcinoma.
    Grude, P
    Conti, F
    Louvel, A
    Lecureur, V
    Fardel, O
    Calmus, Y
    HEPATOLOGY, 1997, 26 (04) : 1314 - 1314
  • [44] Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma
    Pinto-de-Sousa, J
    Silva, F
    David, L
    Leitao, D
    Seixas, M
    Pimenta, A
    Cardoso-de-Oliveira, M
    HISTOPATHOLOGY, 2004, 44 (04) : 323 - 331
  • [45] EXPRESSION OF MUTANT P53 PROTEIN IN BOWENS DISEASE
    MCKEE, PH
    SLATER, SD
    SIM, CS
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 98 (04) : 544 - 544
  • [46] MUTANT P53 PROTEIN IS EXPRESSED IN BOWENS DISEASE
    SIM, CS
    SLATER, SD
    MCKEE, PH
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 1992, 14 (03) : 195 - 199
  • [47] Antitumor Drugs Targeting Mutant p53 Protein
    Wang, Ruo-Ya
    Zhang, Yuan
    Zhang, Ji-Hong
    Yu, Fei
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2024, 51 (01) : 33 - 46
  • [48] Serum levels of mutant p53 protein in cancer
    Karaloglu, D
    Yasasever, V
    Kizir, A
    Dalay, N
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1996, 15 (04): : 335 - 339
  • [49] Targeting mutant p53 protein to the mitochondrion.
    Donahue, RJ
    Knudsen, TB
    MOLECULAR BIOLOGY OF THE CELL, 1999, 10 : 430A - 430A
  • [50] Mutant p53 mediates survival of breast cancer cells
    L Y Lim
    N Vidnovic
    L W Ellisen
    C-O Leong
    British Journal of Cancer, 2009, 101 : 1606 - 1612